2022 Ljubljana, Slovenia

II-34 Yu-wei Lin
Utilizing model informed drug development to support study design for Tovorafenib (DAY101), a novel, type II, pan RAF kinase inhibitor: a focus on longitudinal safety markers
Wednesday 15:10-16:40